Cost Analysis of Two Treatments for Ovarian Cancer
Author Information
Author(s): Ojeda B, de Sande L M, Casado A, Merino P, Casado M A
Primary Institution: Hospital de la Santa Cruz y San Pablo
Hypothesis
Is pegylated liposomal doxorubicin hydrochloride more cost-effective than topotecan for treating recurrent epithelial ovarian cancer in Spain?
Conclusion
Pegylated liposomal doxorubicin hydrochloride is a more cost-effective treatment option compared to topotecan for patients with recurrent epithelial ovarian cancer.
Supporting Evidence
- PLD had overall comparable efficacy with T.
- Total medical costs were lower with PLD due to fewer adverse event management costs.
- Sensitivity analysis confirmed the robustness of the results favoring PLD.
Takeaway
This study looked at two cancer treatments and found that one is cheaper to use than the other, even though they work about the same.
Methodology
A cost-minimisation analysis was performed comparing the costs of pegylated liposomal doxorubicin hydrochloride and topotecan based on a randomised phase III trial.
Potential Biases
Potential bias due to reliance on expert opinion for resource utilization estimates.
Limitations
The analysis relied on efficacy data from a clinical trial rather than real-world effectiveness data, and resource utilization was based on expert opinion.
Participant Demographics
Patients with recurrent epithelial ovarian cancer who failed a first-line platinum-containing regimen.
Statistical Information
P-Value
P=0.037 for progression-free survival in platinum-sensitive patients; P=0.008 for overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website